Introduction
============

Acute myeloid leukemia (AML), the most common type of leukemia in adults, is a group of heterogeneous malignant disorders characterized by clonal proliferation and differentiation arrest of myeloid progenitor cells.[@b1-ott-10-3635],[@b2-ott-10-3635] A multistep process involving genetic and epigenetic aberrations induces normal hematopoietic stem cells (HSCs) to lose the ability of differentiation to various mature cell lineages, to transform into leukemic stem cells, and to accumulate in the bone marrow (BM).[@b3-ott-10-3635],[@b4-ott-10-3635] Genetic aberrations, involving chromosomal abnormalities (translocation, addition, and deletion) and gene alterations (mutation, deletion, amplification, and translocation), have been implicated in the pathogenesis of leukemia and identified in the special subtypes of AML.[@b5-ott-10-3635]--[@b7-ott-10-3635] During last decades, epigenetic disturbances, such as aberrant DNA promoter methylation and covalent histone modification, have also been demonstrated to play crucial roles in the process of leukemogenesis.[@b8-ott-10-3635]--[@b11-ott-10-3635]

In the past few years, numerous studies have indicated that the pathogenesis of AML involves the abnormal activation of Wnt signaling pathway, which has a key role in extensive cellular processes of hematopoietic progenitor proliferation and differentiation.[@b12-ott-10-3635]--[@b14-ott-10-3635] Wnt signaling pathway comprises the canonical pathway with β-catenin and the non-canonical pathways involving calcium ions and planar cell polarity.[@b15-ott-10-3635]--[@b17-ott-10-3635] Growing evidence suggests that the Wnt signaling pathway plays an important role in normal HSCs maintenance, whereas nuclear β-catenin is a key molecule that mediates transcriptional activation of specific gene expression and is thought to have the most significance in cancer development. Moreover, a number of studies have identified that dysregulation of this pathway by promoter hypermethylation leads to leukemia.[@b18-ott-10-3635]--[@b22-ott-10-3635] Negative regulators of the Wnt signaling pathway, including the *WIF1*, the four mammalian homologues of Dickkopf (*DKK*), and the secreted frizzled-related proteins (SFRPs), are epigenetically silenced in tumor cells.[@b23-ott-10-3635]--[@b26-ott-10-3635]

SFRPs, the largest family among Wnt antagonists, suppress the Wnt signaling pathway by interacting with the frizzled receptor. Four of the five known SFRP genes (SFRP1/2/4/5) have been found to be epigenetically silenced in cancer cells.[@b27-ott-10-3635] Hypermethylation of the above-mentioned four SFRP genes, which were associated with aberrant Wnt signaling activation, has been shown in AML.[@b28-ott-10-3635]--[@b30-ott-10-3635] Furthermore, several studies have suggested that hypermethylation of SFRPs promoter was an adverse risk factor for survival in patients with AML;[@b28-ott-10-3635],[@b30-ott-10-3635],[@b31-ott-10-3635] however, few studies have been conducted in the Chinese population.

Therefore, our study aims to investigate the methylated status of SFRPs promoter and its clinical relevance by real-time quantitative methylation-specific polymerase chain reaction (RQ-MSP) in the Chinese non-M3 AML patients.

Materials and methods
=====================

Patients and samples
--------------------

This study was approved by the Ethics Committee of Affiliated People's Hospital of Jiangsu University. After obtaining informed consent, BM specimens were collected at the time of diagnosis during routine clinical assessment of 139 patients with non-M3 AML. All patients were treated at the Affiliated People's Hospital of Jiangsu University between 2005 and 2015. The BM specimens from 21 healthy volunteers served as controls. The diagnosis and classification of de novo AML patients were established according to the French--American--British (FAB) and World Health Organization (WHO) criteria.[@b32-ott-10-3635],[@b33-ott-10-3635] Karyotypes were analyzed by the conventional R-banding method. Karyotype risk classification was identified as reported previously.[@b34-ott-10-3635] The main clinical and laboratory features of the patients are summarized in [Table 1](#t1-ott-10-3635){ref-type="table"}. The BM mononuclear cells (BMMNCs) were separated by Ficoll--Hypaque gradient.

Cell culture and 5-aza-dC treatment
-----------------------------------

Seven human AML cell lines (SHI-1, THP-1, U937, HEL, HL60, K562, and NB4) (ATCC, Manassas, VA, USA) were routinely cultured in IMDM with 10% fetal bovine serum (ExCell Bio, Shanghai, People's Republic of China) and grown at 37°C in 5% CO~2~ humidified atmosphere. Moreover, HL60 cells were incubated at a final concentration of 0 μM, 0.1 μM, 1 μM, 10 μM, and 50 μM 5-aza-2′-deoxycytidine (5-aza-dC) (Sigma-Aldrich, St Louis, MO, USA) for 72 h. All cells were cultured until harvested for extracting RNA and DNA.

RNA isolation, reverse transcription, and real-time quantitative PCR
--------------------------------------------------------------------

Total RNA was isolated from BMMNCs and AML cell lines using the Trizol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and reverse-transcribed into cDNA.[@b35-ott-10-3635] Primer sequences for SFRPs are listed in [Table 2](#t2-ott-10-3635){ref-type="table"}. Real-time quantitative PCR (RQ-PCR) was carried out for each sample in a final reaction volume of 20 μL, consisting of 0.4 μM of primers, 10 μL of SYBR Premix Ex Taq II, 0.4 μL of 50× ROX (TaKaRa, Tokyo, Japan), and 50 ng of cDNA. RQ-PCR was performed on StepOnePlus (Applied Biosystems, Foster City, CA, USA). PCR program was carried out at 95°C for 30 s, followed by 45 cycles at 95°C for 5 s, at T^1^ (in [Table 2](#t2-ott-10-3635){ref-type="table"}) for 30 s and 72°C for 30 s, and a fluorescence collection step at T^2^ (in [Table 2](#t2-ott-10-3635){ref-type="table"}) for 30 s, then followed by a melting program at 95°C for 15 s, 60°C for 60 s, and 95°C for 15 s. The mRNA abundance of SFRPs gene was calculated relative to the expression of the housekeeping gene (*ABL*).[@b36-ott-10-3635]

DNA isolation, bisulfite modification, and RQ-MSP
-------------------------------------------------

Genomic DNA was isolated using genomic DNA purification kit (Gentra, Minneapolis, MN, USA). According to the manufacturer's instructions, 1 μg of genomic DNA was modified using the CpGenome DNA Modification Kit (Chemicon, Ternecula, Canada). The primers ([Table 2](#t2-ott-10-3635){ref-type="table"}) were designed using the Methylation Primer Express Software v1.0 (Applied Biosystems). RQ-MSP was carried out for each sample in a final reaction volume of 20 μL, containing 0.4 μM of primers, 10 μL of SYBR Premix Ex Taq II, 0.4 μL of 50× ROX (TaKaRa), and 50 ng of bisulfite-treated DNA. RQ-MSP was performed on StepOnePlus (Applied Biosystems). Amplification was carried out at 95°C for 30 s, followed by 40 cycles at 95°C for 5 s at T^1^ (in [Table 2](#t2-ott-10-3635){ref-type="table"}) for 30 s and 72°C for 30 s, and a fluorescence collection step at T^2^ (in [Table 2](#t2-ott-10-3635){ref-type="table"}) for 30 s to collect fluorescence data. The relative level of methylated SFRPs was calculated in relation to the reference *ALU* sequence using the formula: *N*~M-SFRPs~ = (*E*~M-SFRPs~)^ΔCT\ M-SFRPs\ (control-sample)^ ÷ (*E~ALU~*)^ΔCT^ *^ALU^* ^(control-sample)^.[@b37-ott-10-3635]

Gene mutation detection
-----------------------

*NPM1*, *C-KIT*, *DNMT3A*, *IDH1*/*2*, and *N*/*K-RAS* mutations were detected by high-resolution melting analysis (HRMA) as reported previously.[@b38-ott-10-3635]--[@b40-ott-10-3635] To confirm the results of HRMA, all positive samples were detected by direct DNA sequencing, and *C*/*EBPA* and *FLT3*-ITD mutations were directly DNA sequenced.[@b41-ott-10-3635],[@b42-ott-10-3635]

Statistical methods
-------------------

All statistical analyses were performed using the SPSS 17.0 software package (SPSS, Chicago, IL, USA). Fisher's exact test or Pearson's Chi-square analysis was carried out to compare the difference of categorical variables between the patients groups, whereas Mann--Whitney *U* test was carried out to compare the difference of continuous variables between the two groups. Overall survival (OS) curve was plotted according to the Kaplan--Meier method and evaluated using the log-rank test. Correlation between SFRPs methylation and expression was compared by Spearman's correlation test. A *P*-value \<0.05 (two-tailed) was considered to be statistically significant.

Results
=======

Methylation of SFRPs in human leukemic cell lines
-------------------------------------------------

We analyzed the methylated status of SFRP1, SFRP2, SFRP4, and SFRP5 promoter regions in seven human AML cell lines (SHI-1, THP-1, U937, HEL, HL60, K562, and NB4) ([Figure 1](#f1-ott-10-3635){ref-type="fig"}). SFRP1 promoter was fully methylated in five cell lines (THP-1, HEL, HL60, K562, and NB4), SFRP2 promoter was fully methylated in three cell lines (HEL, K562, and NB4) and partially methylated in three cell lines (HL60, U937, and THP-1), SFRP4 promoter was fully methylated in two lines (THP-1 and K562), and SFRP5 promoter was fully methylated in three lines (SHI-1, U937, and NB4).

Methylation of SFRPs in AML patients
------------------------------------

An N~M~-*~SFRP1~*~/~*~2~*~/~*~4~*~/~*~5~* ratio equal to or above the values (deter-mined as the mean +5 standard deviation) was set to define high SFRPs methylation in non-M3 AML samples. SFRPs methylation was found in none of the 21 (0%) controls. The frequencies of aberrant methylation among AML patients were as follows: 30.2% (42/139) for SFRP1, 27.3% (38/139) for SFRP2, 5.0% (7/139) for SFRP4, and 1.4% (2/139) for SFRP5. Hypermethylation of at least one SFRP gene occurred in 51.8% (72/139) of AML patients, and there was significant difference between controls and AML patients (*P*\<0.001). The representative results of RQ-MSP products are shown in [Figure 2](#f2-ott-10-3635){ref-type="fig"}.

Association between SFRPs hypermethylation and clinical characteristics
-----------------------------------------------------------------------

There was no significant difference in the sex, blood parameters, FAB subtypes, and cytogenetic risks between the methylated status of any SFRP gene with the clinical parameters (*P*\>0.05; [Table 1](#t1-ott-10-3635){ref-type="table"}). However, the SFRP1 hyper-methylated patients had higher incidence of *N*/*K-RAS* mutations compared to those without SFRP1 hypermethylation (*P*=0.043), whereas the frequency of SFRPs methylation was higher in patients ≥50 y compared to those \<50 y, especially for SFRP2 (*P*\<0.05).

Association between SFRPs hypermethylation and prognosis
--------------------------------------------------------

The follow-up data were obtained for 85 non-M3 AML patients. The median follow-up duration of the patients was 6 months (range: 0--79 months). There was no significant difference in the rates of complete remission after induction therapy between the patients with SFRPs methylation and those without SFRPs methylation (*P*=0.292; [Table 1](#t1-ott-10-3635){ref-type="table"}). However, the Kaplan--Meier curve showed that the OS time of high SFRPs-methylated AML was shorter than that of low SFRPs-methylated group (median: 5 months vs 7.5 months, *P*=0.036; [Figure 3A](#f3-ott-10-3635){ref-type="fig"}). Furthermore, among cytogenetically normal AML (CN-AML) patients, cases with high SFRPs methylation also had significantly shorter OS than those with low methylation (median: 4 months vs 8 months, *P*=0.035; [Figure 3B](#f3-ott-10-3635){ref-type="fig"}). We further performed a Cox regression multivariate analysis adjusting for prognosis-related factors (age, white blood cells, and karyotype), and revealed that SFRPs hypermethylation acts as an independent prognostic biomarker among both non-M3 AML (HR =1.804, *P*=0.026) and CN-AML (HR =2.477, *P*=0.023) patients.

Effect of 5-aza-dC treatment on SFRPs methylation and expression in leukemic cell lines
---------------------------------------------------------------------------------------

To further verify the influence of methylation on SFRPs expression, the HL60 cell line was treated with 5-aza-dC for 72 h. As shown in [Figure 4](#f4-ott-10-3635){ref-type="fig"}, SFRP1/2 expression was significantly upregulated after 5-aza-dC treatment, and the level of SFRP1/2 promoter methylation decreased. Moreover, there was an inverse correlation between SFRP1/2 hypermethylation and the expression level in the HL60 cell line (*r*=−0.975, *P*=0.005 and *r*=−0.975, *P*=0.005, respectively).

Correlation between expression and methylation of SFRPs in AML patients
-----------------------------------------------------------------------

The expression levels of SFRP1 and SFRP2 were examined in 39 non-M3 AML patients with available cDNA specimens. There was no significant correlation between SFRP2 expression and methylation (*r*=−0.171, *P*=0.297). However, a tendency of negative correlation was observed between SFRP1 expression and its promoter methylation (*r*=−0.334, *P*=0.038; [Figure 5](#f5-ott-10-3635){ref-type="fig"}).

Discussion
==========

Wnt signaling pathway has a crucial role in extensive cellular processes of differentiation and proliferation of hematopoietic progenitor. The aberrant activation of this pathway contributes to leukemogenesis. To further verify the role of epigenetic dysregulation of Wnt antagonists SFRPs in leukemia, our study used quantitative methodology to explore significant methylated status of SFRPs promoter in non-M3 AML patients.

In this study, we investigated the correlations of hypermethylation of SFRPs gene promoter with clinical features in non-M3 Chinese AML patients. Previous studies have estimated the frequency of methylation events in AML patients (SFRP1: 29%--41%, SFRP2: 17%--66%, SFRP4: 0%--9%, and SFRP5: 3%--54%).[@b28-ott-10-3635],[@b30-ott-10-3635],[@b31-ott-10-3635],[@b43-ott-10-3635],[@b44-ott-10-3635] However, Shen et al found that the frequency of promoter methylation for SFRP1/2/4/5 genes was 33.9%, 25.4%, 6.8%, and 11.9%, respectively.[@b45-ott-10-3635] From our results, we found that the frequency of promoter methylation was quite close to the result obtained by Shen et al. It can be seen that different races may result in different outcomes. Moreover, we used RQ-MSP, which belongs to one of the semi-quantitative methodologies that provides an advantage for PCR-based assays with the use of melting curve analysis (MCA) minimizing the inclusion of false positives.[@b46-ott-10-3635],[@b47-ott-10-3635] RQ-MSP was able to provide an important consideration for identifying significant methylation events and eliminating very low levels of methylation that are unlikely to confer biological impact. Thus, it can be seen that variability could be caused by methodological differences. Moreover, Cheng et al found that the frequency of aberrant SFRPs promoter methylation correlated significantly with an increased age.[@b44-ott-10-3635] Similarly, our study also proved the fact that increase in age is associated with the increased frequency of SFRPs methylation.

Furthermore, for the clinical and hematological parameters, previous studies have found the significance of gene mutations including *CEBPA* and *N*/*K-RAS*. Cheng et al found the association between SFRP1 hypermethylation and *CEBPA* mutations,[@b44-ott-10-3635] but we did not identify any correlation between SFRP1 methylation and *CEBPA* mutations. Nevertheless, Takeda et al observed that methylation of SFRP2 promoter occurred more frequently in *K-RAS*-mutated colorectal cancers,[@b48-ott-10-3635] yet our data showed the potential association between SFRP1 hypermethylation and *N*/*K-RAS* mutations. The discrepancies in results may also have been caused by the difference in races and number of samples Thus, further studies are required to confirm the results and identify the underlying molecular mechanism.

Further studies should analyze the association between SFRP1/2 hypermethylation and transcriptional downregulation, which could be a potential mechanism leading to the abnormal Wnt signaling pathway. In our study, we have confirmed that aberrant CpG island methylation of SFRP1/2 near the transcriptional start site is associated with gene silencing in the HL60 cell line. To further confirm the role of the epigenetic dysregulation of Wnt antagonists SFRPs in leukemia, we examined the specimens of non-M3 AML patients. Jost et al demonstrated that promoter hypermethylation of SFRP2 was associated with transcriptional downregulation in primary AML.[@b30-ott-10-3635] However, in our study, we found that there was no significant correlation between SFRP2 expression and methylation. In contrast, there was an association between SFRP1 hypermethylation and transcriptional downregulation in non-M3 AML. Similarly, Reins et al demonstrated a significant transcriptional downregulation of SFRP1 in myelodysplastic syndrome.[@b49-ott-10-3635] Jost et al confirmed the frequent epigenetic dysregulation of the Wnt antagonists SFRP1/2/4/5 by aberrant promoter hypermethylation in multiple myeloma.[@b50-ott-10-3635] Thus, our data supported the hypothesis that the epigenetic dysregulation could contribute to the abnormal Wnt signaling pathway, which may be related to AML. Therefore, we need further studies to analyze in detail the functional role of SFRPs.

It is worth noting that hypermethylation of SFRPs predicts poor prognosis in non-M3 AML. Numerous studies have indicated that promoter methylation of SFRPs and other Wnt modulators carried prognostic implications for AML.[@b28-ott-10-3635],[@b30-ott-10-3635],[@b31-ott-10-3635] For instance, Griffiths et al found that SFRP2/5 methylations were associated with poorer disease-free survival and OS in CN-AML.[@b31-ott-10-3635] Jost et al reported that SFRP2 methylation was an adverse risk factor for survival in core binding factor AML.[@b30-ott-10-3635] Although our results have not found a relationship between the hypermethylation of a single member of SFRPs and a prognosis, we confirmed that the OS time of the high SFRPs-methylated group in non-M3 AML was shorter than that of the low group. Furthermore, among CN-AML patients, cases with the high SFRPs-methylated group also had significantly shorter OS than those with low SFRPs-methylated one. Similarly, Valencia et al showed that the methylation of SFRPs and *DKKs* was associated with a poorer prognosis only in young adult patients with intermediate-risk cytogenetics.[@b28-ott-10-3635] Our results were consistent with the above findings. Therefore, we indicated that the hypermethylation of SFRPs predicts poor prognosis and may be useful as a biomarker for further prognostic stratification in cytogenetically defined risk groups in non-M3 AML.

Quantitative methodology may be an important consideration for identifying significant methylation events. Thus, we used a quantitative methodology to analyze hypermethylation of SFRPs and arrived at an important conclusion that promoter hypermethylation of SFRP1/2 appears to be a common event and may have a poor impact on the prognosis in non-M3 AML.

Conclusion
==========

Both whole cohort and CN patients with high SFRPs-methylated group showed a shorter OS compared to those with low group. The alteration of SFRP1/2 expression was inversely correlated with change of SFRP1/2 methylation in leukemic cell line HL60. These findings suggested that the hypermethylation of SFRPs promoter was an adverse risk factor for survival in non-M3 AML.
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![Electrophoresis results of RQ-MSP products in leukemic cell lines.\
**Abbreviations:** RQ-MSP, real-time quantitative methylation-specific polymerase chain reaction; M, methylation; U, unmethylation.](ott-10-3635Fig1){#f1-ott-10-3635}

![Electrophoresis results of RQ-MSP products of SFRPs in AML patients.\
**Notes:** 1: GeneRuler™ 100-bp DNA ladder; 2 and 3: two controls; 4--11: samples of non-M3 AML patients (four patients with high SFRP1/SFRP2 expression and the other four with low SFRP1/SFRP2 expression); 12: positive control; 13: negative control.\
**Abbreviations:** RQ-MSP, real-time quantitative methylation-specific polymerase chain reaction; SFRPs, secreted frizzled-related proteins; AML, acute myeloid leukemia; M, methylation; U, unmethylation.](ott-10-3635Fig2){#f2-ott-10-3635}

![Overall survival of non-M3 AML patients: (**A**) all patients; (**B**) cytogenetically normal patients.\
**Abbreviations:** AML, acute myeloid leukemia; SFRPs, secreted frizzled-related proteins.](ott-10-3635Fig3){#f3-ott-10-3635}

![HL60 with 5-aza-dC treatment.\
**Notes:** Relative changes in (**A**) SFRP1 and (**B**) SFRP2 expression levels and (**C**) SFRP1 and (**D**) SFRP2 methylation levels before and after treatment of HL60 cell line with the demethylating agent 5-aza-dC for 72 h at 0 μM, 0.1 μM, 1 μM, 10 μM, and 50 μM concentrations. Expression levels of SFRP1 and SFRP2 were determined by RQ-PCR and normalized to the housekeeping gene *ABL*. Methylation levels of SFRP1 and SFRP2 were determined by RQ-MSP and normalized to the housekeeping gene *ALU*. Error bars indicate standard deviation.\
**Abbreviations:** 5-aza-dC, 5-aza-2′-deoxycytidine; RQ-PCR, real-time quantitative polymerase chain reaction; RQ-MSP, real-time quantitative methylation-specific polymerase chain reaction.](ott-10-3635Fig4){#f4-ott-10-3635}

![Correlation between SFRP1 hypermethylation and expression level in non-M3 AML patients and HL60 cell line (since the value was lg function conversion, methylation and expression level at zero was excluded).\
**Abbreviation:** AML, acute myeloid leukemia.](ott-10-3635Fig5){#f5-ott-10-3635}

###### 

Correlations of hypermethylation of SFRPs gene promoter with clinical features in non-M3 AML patients

  Patient's parameters                                        SFRP1 methylation   SFRP2 methylation    SFRPs methylation   Total (n=139)                                                                                          
  ----------------------------------------------------------- ------------------- -------------------- ------------------- ------------------- ------------------- ----------- ------------------- ------------------ ----------- -------------------
  Sex, male/female                                            27/15               59/38                0.710               22/16               64/37               0.563       44/28               42/25              0.863       86/53
  Median age (range) (years)                                  56 (18--86)         49.5 (18--85)        0.316               56.5 (18--86)       47 (18--85)         0.095       55.5 (18--86)       45.5 (18--85)      0.106       52 (18--86)
  Median WBCs (range) (×10^9^/L)                              27.7 (0.7--528.0)   18.45 (0.8--300.0)   0.671               17.7 (0.7--528.0)   21.5 (0.8--528.0)   0.439       27.7 (0.7--528.0)   16.85 (0.8--300)   0.740       18.7 (0.7--528.0)
  Median hemoglobin (range) (g/L)                             83 (32--114)        72 (34--147)         0.411               71 (32--119)        74.5 (33--147)      0.401       75 (33--123)        74 (32--147)       0.303       74 (32--147)
  Median platelets (range) (×10^9^/L)                         31 (6--190)         41.5 (3--399)        0.319               36 (7--264)         39 (3--399)         0.817       37 (6--264)         39 (3--399)        0.881       38 (3--399)
  BM blasts (range) (%)                                       46 (15.5--99)       52.5 (6--94.5)       0.299               68 (10.5--97.5)     47.0 (6--99)        0.062       52.0 (10.5--99)     51.25 (6--94.5)    0.476       51.5 (6--99)
  Age (years)                                                                                          0.526                                                       **0.011**                                          **0.041**   
   \<50                                                       16 (38%)            47 (48%)                                 11 (29%)            52 (51%)                        26 (36%)            37 (55%)                       63 (45%)
   ≥50                                                        24 (57%)            47 (48%)                                 27 (71%)            44 (44%)                        44 (61%)            27 (40%)                       71 (51%)
   No data                                                    2 (5%)              3 (4%)                                   0 (0%)              5 (5%)                          2 (3%)              3 (5%)                         5 (4%)
  FAB                                                                                                  0.356                                                       0.078                                              0.482       
   M0                                                         0 (0%)              1 (1%)                                   1 (3%)              0 (0%)                          1 (1%)              0 (0%)                         1 (1%)
   M1                                                         3 (7%)              12 (12%)                                 8 (21%)             7 (7%)                          8 (11%)             7 (10%)                        15 (11%)
   M2                                                         17 (41%)            50 (52%)                                 18 (47%)            49 (49%)                        30 (42%)            37 (56%)                       67 (48%)
   M4                                                         11 (26%)            20 (21%)                                 7 (18%)             24 (24%)                        20 (28%)            11 (16%)                       31 (22%)
   M5                                                         8 (19%)             12 (12%)                                 4 (11%)             16 (16%)                        10 (14%)            10 (15%)                       20 (14%)
   M6                                                         3 (7%)              2 (2%)                                   0 (0%)              5 (5%)                          3 (4%)              2 (3%)                         5 (4%)
  Karyotype classification                                                                             0.588                                                       0.615                                              0.899       
   Favorable                                                  8 (19%)             11 (11%)                                 3 (8%)              16 (16%)                        9 (13%)             10 (15%)                       19 (14%)
   Intermediate                                               27 (64%)            70 (73%)                                 28 (73%)            69 (69%)                        50 (68%)            47 (70%)                       97 (69%)
   Poor                                                       4 (10%)             11 (11%)                                 4 (11%)             11 (11%)                        9 (13%)             6 (9%)                         15 (11%)
   No data                                                    3 (7%)              5 (5%)                                   3 (8%)              5 (5%)                          4 (6%)              4 (6%)                         8 (6%)
  Karyotype                                                                                            0.714                                                       0.780                                              0.989       
   Normal                                                     24 (57%)            54 (56%)                                 22 (57%)            56 (56%)                        41 (57%)            37 (56%)                       78 (56%)
   t(8;21)                                                    7 (17%)             11 (11%)                                 3 (8%)              15 (15%)                        8 (11%)             10 (15%)                       18 (13%)
   11q23                                                      1 (2%)              1 (1%)                                   1 (3%)              1 (1%)                          1 (1%)              1 (1%)                         2 (1%)
   Complex                                                    2 (5%)              9 (9%)                                   3 (8%)              8 (8%)                          6 (8%)              5 (7%)                         11 (8%)
   Others                                                     5 (12%)             17 (18%)                                 6 (16%)             16 (16%)                        12 (17%)            10 (15%)                       22 (16%)
   No data                                                    3 (7%)              5 (5%)                                   3 (8%)              5 (5%)                          4 (6%)              4 (6%)                         8 (6%)
  Gene mutation[\*](#tfn1-ott-10-3635){ref-type="table-fn"}                                                                                                                                                                       
   *C/EBPA* (±)                                               6/34 (15%)          19/76 (20%)          0.630               6/32 (16%)          19/78 (20%)         0.637       10/60 (14%)         15/50 (23%)        0.267       25/110 (19%)
   *NPM1* (±)                                                 4/36 (10%)          14/81 (15%)          0.585               7/31 (18%)          11/86 (11%)         0.398       10/60 (14%)         8/57 (12%)         0.804       18/117 (13%)
   *FLT3-ITD* (±)                                             2/38 (5%)           9/86 (9%)            0.506               4/34 (11%)          7/90 (7%)           0.728       5/65 (7%)           6/59 (9%)          0.758       11/124 (8%)
   *DNMT3A* (±)                                               1/39 (3%)           7/88 (7%)            0.435               2/36 (5%)           6/91 (6%)           1.000       3/67 (4%)           5/60 (8%)          0.481       8/127 (6%)
   *IDH1/2* (±)                                               3/37 (8%)           8/87 (8%)            1.000               4/34 (11%)          7/90 (7%)           0.728       6/64 (9%)           5/60 (8%)          1.000       11/124 (8%)
   *C-KIT* (±)                                                2/38 (5%)           10/85 (11%)          0.352               2/36 (5%)           10/87 (10%)         0.509       3/67 (4%)           9/56 (14%)         0.070       12/123 (9%)
   *N/K-RAS* (±)                                              9/31 (23%)          8/87 (8%)            **0.043**           5/33 (13%)          12/85 (12%)         1.000       11/59 (16%)         6/59 (9%)          0.306       17/118 (13%)
  CR (±)                                                      11/19 (37%)         25/38 (40%)          0.823               9/18 (33%)          27/39 (41%)         0.640       18/35 (34%)         18/22 (45%)        0.292       36/57 (39%)

**Note:**

Percentage was equal to the number of mutated patients divided by total cases in each group. Bold values indicate positive results.

**Abbreviations:** SFRPs, secreted frizzled-related proteins; AML, acute myeloid leukemia; WBCs, white blood cells; BM, bone marrow; FAB, French-American-British; CR, complete remission.

###### 

Primer sequences of SFRPs for RQ-PCR and RQ-MSP

  Primer        Sequence                               Size (bp)   T^1^ (°C)   T^2^ (°C)
  ------------- -------------------------------------- ----------- ----------- -----------
  Expression                                                                   
   SFRP1-F      5′-AGATGCTTAAGTGTGACAAGTTCC-3′         130         64          85
   SFRP1-R      5′-TCAGATTTCAACTCGTTGTCACAG-3′                                 
   SFRP2-F      5′-TGAGTGCGACCGTTTCCC-3′               298         62          81
   SFRP2-R      5′-GAGCCACAGCACCGATTT-3′                                       
   SFRP4-F      5′-GTACAGGAAAGGCCTCTTGATG-3′           154         68          80
   SFRP4-R      5′-TGCAGCCACTCCTCTGCAC-3′                                      
   SFRP5-F      5′-GCGCCCAGTGTGAGATGG-3′               115         65          82
   SFRP5-R      5′-TTCCGGTCCCCATTCTCTATC-3′                                    
  Methylation                                                                  
   SFRP1-M-F    5′-TGTAGTTTTCGGAGTTAGTGTCGCGC-3′       126         65          82
   SFRP1-M-R    5′-CCTACGATCGAAAACGACGCGAACG-3′                                
   SFRP1-U-F    5′-GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT-3′   135         60          
   SFRP1-U-R    5′-CTCAACCTACAATCAAAAACAACACAAACA-3′                           
   SFRP2-M-F    5′-GGGTCGGAGTTTTTCGGAGTTGCGC-3′        138         68          83
   SFRP2-M-R    5′-CCGCTCTCTTCGCTAAATACGACTCG-3′                               
   SFRP2-U-F    5′-TTTTGGGTTGGAGTTTTTTGGAGTTGTGT-3′    144         65          
   SFRP2-U-R    5′-AACCCACTCTCTTCACTAAATACAACTCA-3′                            
   SFRP4-M-F    5′-GGGTGATGTTATCGTTTTTGTATCGAC-3′      112         67          81
   SFRP4-M-R    5′-CCTCCCCTAACGTAAACTCGAAACG-3′                                
   SFRP4-U-F    5′-GGGGGTGATGTTATTGTTTTTGTATTGAT-3′    116         67          
   SFRP4-U-R    5′-CACCTCCCCTAACATAAACTCAAAACA-3′                              
   SFRP5-M-F    5′-AAGATTTGGCGTTGGGCGGGACGTTC-3′       136         68          85
   SFRP5-M-R    5′-ACTCCAACCCGAACCTCGCCGTACG-3′                                
   SFRP5-U-F    5′-GTAAGATTTGGTGTTGGGTGGGATGTTT-3′     141         69          
   SFRP5-U-R    5′-AAAACTCCAACCCAAACCTCACCATACA-3′                             

**Notes:** T^1^: annealing temperature; T^2^: temperature of fluorescence collection.

**Abbreviations:** SFRPs, secreted frizzled-related proteins; RQ-PCR, real-time quantitative polymerase chain reaction; RQ-MSP, real-time quantitative methylation-specific polymerase chain reaction.

[^1]: These authors contributed equally to this work
